The decision on whether to distribute additional doses will be taken by the national authorities, EZA announced.
The Agency’s experts looked at data showing that antibody levels were rising after receiving an additional dose of Pfizer and BioNTech Covid-19.
The ESA stated that the risk of inflammatory heart disease and other very rare side effects after additional doses is unknown and is being closely monitored.
In rare cases, myocarditis has been reported in humans, especially in young men, after vaccination with Pfizer and BioNTech Covid-19.
The Covid-19 vaccine developed by Moderna and the Pfizer and BioNTech vaccine have been approved for booster doses in people with very weakened immune systems for at least 28 days after the second dose.
Sometimes two doses are not enough to produce enough antibodies in immunocompromised people, such as people who have had an organ transplant.
Although there is no direct evidence that the additional dose will protect such people from developing Covid-19, it is thought that at least some patients will have this protection, the EZA said.
